These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 31673960)

  • 1. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
    Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
    Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
    Horton DB; Onel KB; Beukelman T; Ringold S
    J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
    Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
    Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
    Chang CY; Meyer RM; Reiff AO
    Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study.
    Aires PP; Terreri MTRA; Silva VBM; Vieira MM; Len CA
    Acta Reumatol Port; 2021; 46(2):120-125. PubMed ID: 34226433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration.
    Simonini G; Ferrara G; Pontikaki I; Scoccimarro E; Giani T; Taddio A; Meroni PL; Cimaz R
    Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1046-1051. PubMed ID: 28973842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When to stop medication in juvenile idiopathic arthritis.
    Abel D; Weiss PF
    Curr Opin Rheumatol; 2023 Sep; 35(5):265-272. PubMed ID: 37139831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial.
    Gerss J; Tedy M; Klein A; Horneff G; Miranda-Garcia M; Kessel C; Holzinger D; Stanevica V; Swart JF; Cabral DA; Brunner HI; Foell D
    Ann Rheum Dis; 2022 Jul; 81(7):990-997. PubMed ID: 35260388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
    Foell D; Wulffraat N; Wedderburn LR; Wittkowski H; Frosch M; Gerss J; Stanevicha V; Mihaylova D; Ferriani V; Tsakalidou FK; Foeldvari I; Cuttica R; Gonzalez B; Ravelli A; Khubchandani R; Oliveira S; Armbrust W; Garay S; Vojinovic J; Norambuena X; Gamir ML; García-Consuegra J; Lepore L; Susic G; Corona F; Dolezalova P; Pistorio A; Martini A; Ruperto N; Roth J;
    JAMA; 2010 Apr; 303(13):1266-73. PubMed ID: 20371785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
    Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey.
    Currie GR; Groothuis-Oudshoorn CGM; Twilt M; Kip MMA; IJzerman MJ; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung R; Marshall DA
    Clin Rheumatol; 2023 Aug; 42(8):2173-2180. PubMed ID: 37202606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?
    Nieto-González JC; Garulo DC; Boteanu A; Trives-Folguera L; García-Fernández A; Navarro PG; Robledillo JCL; Monteagudo-Saéz I
    J Rheumatol; 2023 Oct; 50(10):1326-1332. PubMed ID: 37527855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of medication withdrawal in patients with non-systemic juvenile idiopathic arthritis in Japan using a web-based survey.
    Ebato T; Kishi T; Akamine K; Nozawa T; Imagawa T; Bando Y; Miyamae T
    Mod Rheumatol; 2024 Oct; 34(6):1231-1237. PubMed ID: 38441307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort.
    Guzman J; Henrey A; Loughin T; Berard RA; Shiff NJ; Jurencak R; Huber AM; Oen K; Gerhold K; Feldman BM; Scuccimarri R; Houghton K; Chédeville G; Morishita K; Lang B; Dancey P; Rosenberg AM; Barsalou J; Bruns A; Watanabe Duffy K; Benseler S; Duffy CM; Tucker LB;
    J Rheumatol; 2019 Jun; 46(6):628-635. PubMed ID: 30647178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.